



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



AZD4573

Cat. No.:	HY-112088
CAS No.:	2057509-72-3
Molecular Formula:	C ₂₂ H ₂₈ ClN ₅ O ₂
Molecular Weight:	429.94
Target:	CDK
Pathway:	Cell Cycle/DNA Damage
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (116.30 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.3259 mL	11.6295 mL	23.2591 mL
		5 mM		0.4652 mL	2.3259 mL	4.6518 mL
		10 mM		0.2326 mL	1.1630 mL	2.3259 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.84 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.84 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil					
	Solubility: ≥ 2.08 mg/mL (4.84 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	AZD4573 is a potent and highly selective CDK9 inhibitor (IC ₅₀ of <4 nM) that enables transient target engagement for the treatment of hematologic malignancies ^[1] .
IC ₅₀ & Target	CDK9 4 nM (IC ₅₀)
In Vitro	Short-term treatment with AZD4573 led to a rapid dose- and time-dependent decrease in cellular pSer2-RNAPII, resulting in

	activation of caspase 3 and cell apoptosis in a broad range of haematological cancer cell lines (e.g. caspase activation EC₅₀ 13.7 nM in an acute myeloid leukemia model MV4-11) ^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	AZD4573 exhibits a short half-life in multiple species (less than one hour in rat, dog and monkey) and good solubility for intravenous administration^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Acta Pharm Sin B. 2023 May 26.
- Cancer Res. 2023 Oct 6.
- Cell Rep. 2020 Apr 7;31(1):107485.
- Int J Mol Sci. 2022 Feb 24;23(5):2493.
- PLoS One. 2020 Jun 19;15(6):e0232068.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Bernard Barlaam, et al. Abstract 1650: Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of hematologic malignancies. Cancer Research. July 2018. 78(13): Supplement.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA